Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Dennis Slamon, MD
University of California, Los Angeles
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
29 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Cancer Center of Adjara Autonomous Republic
Batumi, Adjara, Georgia
- Saint Nikolozi Surgery and Oncological Centre
Kutaisi, Imereti, Georgia
- Unimed Adjara - Oncology Center
Kutaisi, Imereti, Georgia
- Cancer Research Center
Tbilisi, Georgia
- Health House
Tbilisi, Georgia
- Institute of Clinical Oncology
Tbilisi, Georgia
- Multiprofile Clinic Consilium Medulla
Tbilisi, Georgia
- New Vision University Hospital
Tbilisi, Georgia
- Research Institute of Clinical Medicine
Tbilisi, Georgia
- S. Khechinashvili, University Hospital
Tbilisi, Georgia
- Uab Comprehensive Cancer Center
Birmingham, Alabama, United States
- Cbcc Global Research at Comprehensive Blood and Cancer Center
Bakersfield, California, United States
- St. Jude Medical Center
Fullerton, California, United States
- Los Angeles Hematology Oncology Medical Group
Glendale, California, United States
- Torrance Memorial Cancer Care Associates
Redondo Beach, California, United States
- Slo Oncology and Hematology Health Center
San Luis Obispo, California, United States
- Central Coast Medical Oncology Group
Santa Maria, California, United States
- Ucla Hematology/oncology - Santa Monica
Santa Monica, California, United States
- Saint Mary'S Regional Cancer Center
Grand Junction, Colorado, United States
- Office of Human Research
Hollywood, Florida, United States
- Orlando Health, Inc.
Orlando, Florida, United States
- Ft. Wayne Hematology and Oncology
Fort Wayne, Indiana, United States
- Ft. Wayne Medical Oncology & Hematology, Inc
Fort Wayne, Indiana, United States
- Cancer Center of Kansas
Wichita, Kansas, United States
- Frauenshuh Cancer Center at Park Nicollet Health Service
Saint Louis Park, Minnesota, United States
- Saint Barnabas Medical Cancer Center
Livingston, New Jersey, United States
- Hope Women'S Cancer Centers
Asheville, North Carolina, United States
- Wake Forest Baptist Medical Center
Winston-Salem, North Carolina, United States
- Texas Oncology-Baylor Charles A. Sammons Cancer Center
Dallas, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 May 2016
- Primary completion
- 31 Mar 2021
- Completion
- 31 Mar 2021
- Last update posted
- 4 Dec 2024
- Registered enrollment
- 89
- Registry id
- NCT02708680
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.